Form Type: 4

SEC EDGAR Link
Accession Number:0001209191-21-003235
Date:2021-01-08
Issuer: NEUROCRINE BIOSCIENCES INC (NBIX)
Original Submission Date:

Reporting Person:

GORMAN KEVIN CHARLES
12780 EL CAMINO REAL
SAN DIEGO, CA 92130

Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
Title of SecurityTransaction Date2a. Deemed Execution Date Transaction CodeSharesAcquired or DisposedPrice per share 5. Amount of Securities Beneficially Owned Following Reported Transaction 6. Ownership Form Direct or IndirectNature of Indirect Ownership
COMMON STOCK 2021-01-08 M 143,449 a $8.66 584,520 direct
COMMON STOCK 2021-01-08 S 143,449 d $110.21 441,071 direct
COMMON STOCK 2021-01-08 M 164,801 a $8.65 605,872 direct
COMMON STOCK 2021-01-08 S 164,801 d $110.22 441,071 direct
Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, convertible securities
Title of Derivative Security Conversion or Exercise Price of Derivative Security Transaction Date Deemed Execution Date Transaction Code Number of Derivative Securities Acquired (A) or Disposed of (D) Date ExercisableExpiration Date Title and Amount of Securities Underlying Derivative Security Price of Derivative Security Number of derivative Securities Beneficially Owned Following Reported Transaction(s) Ownership Form: Direct (D) or Indirect (I) Nature of Indirect Beneficial Ownership
NON-QUALIFIED STOCK OPTION 8.66 2021-01-08 deemed execution date M 143,449 (d) 2022-01-12 common stock 143,449 $8.66 0 direct
NON-QUALIFIED STOCK OPTION 8.65 2021-01-08 deemed execution date M 164,801 (d) 2023-01-10 common stock 164,801 $8.65 0 direct
Footnotes
IDfootnote
f1 the disposition reported in this form 4 was effected by a broker pursuant to instructions set forth in a rule 10b5-1 trading plan adopted by the reporting person at least 60 days prior to the transaction date in box 3 above. additionally, issuer policy restricts the reporting person from amending or otherwise modifying any 10b5-1 trading plan subsequent to adoption of the plan.
f2 represents a weighted average sales price per share. these shares were sold in multiple transactions at prices ranging from $110.00 to $111.24. the reporting person has provided to the issuer, and will provide to any security holder of the issuer or the sec staff, upon request, information regarding the number of shares sold at each price within the range.
f3 represents a weighted average sales price per share. these shares were sold in multiple transactions at prices ranging from $110.00 to $111.19. the reporting person has provided to the issuer, and will provide to any security holder of the issuer or the sec staff, upon request, information regarding the number of shares sold at each price within the range.
f4 option granted january 12, 2012 and vested monthly over four years.
f5 option granted january 10, 2013 and vested monthly over four years.

Elevate your investments